EP0942756A2 - Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche - Google Patents

Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche

Info

Publication number
EP0942756A2
EP0942756A2 EP97948710A EP97948710A EP0942756A2 EP 0942756 A2 EP0942756 A2 EP 0942756A2 EP 97948710 A EP97948710 A EP 97948710A EP 97948710 A EP97948710 A EP 97948710A EP 0942756 A2 EP0942756 A2 EP 0942756A2
Authority
EP
European Patent Office
Prior art keywords
radical
general formula
independently
dye
compounds according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97948710A
Other languages
German (de)
English (en)
Inventor
Jonathan Turner
Thomas Dyrks
Wolfhard Semmler
Kai Licha
Björn Riefke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Institut fuer Diagnostikforschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut fuer Diagnostikforschung GmbH filed Critical Institut fuer Diagnostikforschung GmbH
Publication of EP0942756A2 publication Critical patent/EP0942756A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
    • C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B56/00—Azo dyes containing other chromophoric systems
    • C09B56/16—Methine- or polymethine-azo dyes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Definitions

  • NIR radiation near-infrared radiation
  • the invention relates to compounds for in vivo and in vitro diagnosis of neurodegenerative diseases by means of near infrared radiation (NIR radiation), the use of these compounds as optical diagnostics and diagnostic agents containing these compounds.
  • NIR radiation near infrared radiation
  • AD Alzheimer's disease
  • the incidence of AD increases with the age of the patient and reaches values of 40% -50% in the age group between 85 and 90 years.
  • AD can only be diagnosed post mortem with certainty by examining the brains of the patients during an autopsy.
  • the brains of Alzheimer's patients contain many characteristic amyloid plaques in the neural tissue and in the vicinity of blood vessels, which are surrounded by dystrophied neurites and neurofibrillary "tangles". Furthermore, the brains of Alzheimer's patients have a small number of synapses.
  • amyloid plaques consist inter alia of the amyloid- ⁇ -peptide (Aß), a fragment of the ⁇ -amyloid precursor protein (APP) consisting of 40 to 42 amino acids (Master, CL, Simms, G., Weinman, NA, et al. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sei USA 1985, 82: 4245-9; Kang, J., Lemaire, HG, Unterbeck, A. et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-sur- face receptor. Nature 1987, 325: 733-6).
  • the number of plaques does not correlate with the degree of advanced dementia, but is an early and reliable diagnostic for the occurrence of Alzheimer's disease. This leads to the hypothesis that the first deposits of Aß take place long before the manifestation of AD and before the first clinical symptoms appear (Hardy, L., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer ' s disease. Trends Pharmacol Sci 1991, 12: 383-8).
  • a method that quantitatively records the amyloid plaques early before the patient's death would have a major impact on further research into AD and on the development of new effective therapy concepts against AD.
  • AD amyloid plaques
  • the extent of AD is today only indirectly diagnosed on the basis of brain volume or brain areas affected by metabolic disorders (MRI and PET).
  • MRI and PET metabolic disorders
  • the serious disadvantage of these methods is the only indirect detection of AD, which is often associated with high statistical fluctuation ranges of the results.
  • the sensitivity of these methods to detection of direct detection of amyloid plaques can therefore be assessed as low.
  • both the detection of the non-absorbed radiation in the form of a transmission display and the fluorescence radiation emitted after irradiation with near-infrared light can provide tissue-specific information.
  • the object of the invention is therefore to provide new compounds which overcome the disadvantages of the prior art.
  • F is a dye signal molecule which has at least one absorption maximum in the range from 600 to 1200 nm
  • A is a biomolecule which binds to ⁇ -amyloid plaques
  • B is a dye which binds to ⁇ -amyloid plaques
  • W is a to ⁇ -amyloid -Plaques-binding hydrophilic, low-molecular structural element
  • n and o stands for an integer 3 - 20
  • n and n independently of one another represent a number 0, 1 or 2
  • o represents an integer 0, 1, 2, 3 or 4, with the proviso that the sum of 1, n and o is> 1
  • the compounds according to the invention attach to the amyloid plaques or constituents of the amyloid plaques, bind or accumulate there and thus to unify and Increase the absorption and fluorescence of these areas to be detected.
  • the in vivo detection of ⁇ -amyloid deposits using NIR radiation requires dyes as contrast agents which have a high absorption and fluorescence quantum yield in the wavelength range from 600 to 1200 nm and bind selectively to ⁇ -amyloid deposits.
  • Dyes from the class of the polymethines have absorption and fluorescence properties which are characterized by high molar absorption coefficients between 600 and 1200 nm and sufficient fluorescence quantum yields. Dyes in this class generally have high photostability.
  • fluorescent dyes are suitable for improving the differentiation between normal and diseased tissue, which accumulate in the diseased tissue or selectively bind to pathologically changed tissue components and have a specific absorption and emission behavior.
  • the compounds of the general formula I according to the invention bind to the ⁇ -amyloid plaques.
  • the change in the (scattered) incident light caused by absorption of the dye and / or the fluorescence induced by the excitation radiation is detected and provides the actual tissue-specific information which enables a statement about the degree of the pathogenic change.
  • such dyes are used as signal molecules F which are covalently linked to ⁇ -amyloid Structures that bind plaques are linked or are substituted with such structures.
  • Compounds of the general formula I according to the invention are those in which, for example, a) 1 and n are zero, m is one and o is 1-4, or b) n and o are zero, m is 3-20 and 1 is 1- 2 stands, or c) 1 and o mean zero, m stands for 1-2 and n stands for 1-2, provided that the sum of n and m is less than or equal to 3.
  • Preferred compounds of general formula I according to the invention are those in which F represents a cyanine, squarilium, croconium, merocyanine or oxonol dye.
  • R 1 to R 4 and R 7 to R 10 independently of one another for a fluorine, chlorine, bromine, iodine atom or a nitro group or for a radical -COOE 1 , -CONE 1 E 2 , -NHCOE 1 , -NHCONHE 1 , -NE ⁇ 2 , -OE 1 , -OSO3E 1 , -SO3E 1 , -SO2NHE 1 , -El, where E 1 and E 2 independently of one another represent a hydrogen atom, a saturated or unsaturated, branched or straight-chain Ci-Cso- alkyl chain, whereby the chain or parts of this chain against appropriate, one or more aromatic or saturated cyclic C5-C6 or bicyclic C can form 1 0 units, and wherein the C ⁇ _-C50-alkyl chain from 0 to 15 oxygen atoms and / or is interrupted by 0 to 3 carbonyl groups and / or is substituted by 0 to 5
  • R5 and R ⁇ independently of one another represent a radical -E 1 with the meaning given above or for a C ⁇ _- C4-sulfoalkyl chain, Q is a fragment
  • R 11 represents a hydrogen, fluorine, chlorine, bromine, iodine atom or a nitro group or a radical -NE ⁇ -E 2 , -OE 1 or -E 1 , where E 1 and E 2 have the meaning given above, stands,
  • R 12 represents a hydrogen atom or a radical E 1 with the meaning given above,
  • b represents a number 0, 2 or 3
  • R 1 ⁇ unc R14 independently of one another represent hydrogen, a saturated or unsaturated, branched or straight-chain Ci - Cio-alkyl chain which can be interrupted by up to 5 oxygen atoms and / or can be substituted by up to 5 hydroxyl groups, and the radicals R 1 ⁇ unc R 14 can be linked to form a 5- or 6-membered ring,
  • p is an integer 2 or 3
  • R 1 ⁇ and d R 2 0 independently of one another are a radical -COOE 1 , -CONE ⁇ 2 , -NHCOE 1 , -NHCONHE 1 , -NE ⁇ 2 , -OE 1 , -OS03H, - SO3H, -E ⁇ -, whereby E ⁇ and E 2 have the meaning given above, with the proviso that E 1 and E 2 are not simultaneously hydrogen atoms,
  • R 21 and R 22 independently of one another for a radical -E 1 with the meaning given above, for a C 1 -C 4 sulfoalkyl chain
  • R 19 , R 20 , R 21 , R 22 , E 1 or E 2 represent a bond to A, B or W with the meaning given above, represents.
  • E 3 represents a mono-, oligo- or polysaccharide with at least one radical -OSO3H,
  • R and R have the meaning given above, R and R independently of one another represent a phenyl ring which is monosubstituted to trisubstituted by hydroxyl, carboxy, sulfate, sulfonate, alkyl or alkoxy or carboxylic acid ester radicals,
  • Compounds of general formula I according to the invention are those in which A is, for example for antibodies, antibody fragments, specific peptides and proteins, receptors, enzymes, enzyme substrates, nucleotides, ribonucleic acids, deoxyribonucleic acids, lipoproteins, carbohydrates, mono-, di- or trisaccharides, linear or branched Oligosaccharides or polysaccharides or
  • Preferred peptides are the ⁇ -amyloid 1-40, 1-42 and 1-43, as well as partial structures and derivatives thereof.
  • the ⁇ -amyloids and partial structures of the ⁇ -amyloids which are modified with the amino acid cysteine are particularly preferred, the binding to the F taking place via the sulfhydryl group of the cysteine using a maleimido structure.
  • Monomeric aminosugars are, for example, glucosamine,
  • Amino sugar carboxylic acids are, for example, glucosamic acid, glucosaminuronic acid, muramic acid, trehalosamine, chondrosine and derivatives, chitotriose.
  • Preferred compounds of general formula I are those in which the bond to F between the amino group of the sugar and carboxy group of the dye to form an amide group.
  • Mono- to oligomeric saccharides are aldo- and ketotrioses to aldo- and ketoheptoses, ketooctoses and ketononoses, anhydro sugars, cyclites, amino and diamino sugars, deoxy sugars, aminodeoxy sugars, monocarboxylic acids, amino sugar carboxylic acids, aminocyclites, phosphorus-containing derivatives Mono- to oligomers.
  • polysaccharides are fucoidan, arabinogalactan, chondroitin and sulfates, dermatan, heparin, heparan, heparitin, hyaloronic acid, keratan, polygalacturonic acid, polyglucuronic acid, polymannuronic acid, inulin, polylactose, polylactosamine, aminosucoseopin, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosysyl acid, polyinosy
  • Particularly preferred mono-, oligo- and polysaccharides are sulfated or polysulfated structures.
  • Sulfated structures are, for example, glucosamine-3-sulfate, glucosamine-6-sulfate and those structures which are formed by sulfating with suitable reagents Mono-, di-, tri- to oligo- and polysaccharides described above can be obtained
  • Dye structures B are diazo dyes that are covalently bound to the signaling molecules. Suitable diazo dyes are, for example, Congo red, Chrysamine G, Evans
  • Preferred compounds of the general formula I are those in which B is a diazo dye of the general formula VIII
  • R! 5 and R! independently of one another with one or more hydroxy, carboxy, amino, sulfonic acid, alkoxycarbonyl, alkylamino, dialkylamino, alkoxy, with up to 6 carbon atoms in the alkyl radical, or arylsulfonyl groups with up to 9 carbon atoms in the aryl radical, substituted phenyl or naphthyl radical, or for a dye F, R 17 and R 18 independently of one another represent a hydroxyl, carboxy, sulfonic acid, alkyl, alkoxy radical having up to 6 carbon atoms.
  • Preferred compounds of the general formula I according to the invention are also those in which W represents a radical -OSO3H or -SO3H, an unbranched, branched, cyclic or polycyclic alkyl, alkenyl, polyalkenyl, alkynyl, aryl, Alkylaryl or arylalkyl radical with up to 60 carbon atoms, which is substituted with up to 5 hydroxyl groups, up to 3 carboxylic acid groups and at least one radical -OSO3H or -SO3H.
  • Preferred compounds according to the general formula I are those in which W denotes a sulfated structure which can be prepared by sulfating corresponding hydroxyl compounds.
  • Amino alcohols are suitable, for example, where the linkage has taken place between the amino group and the carboxy group of the dye to form an amide group and the hydroxyl groups are sulfated.
  • Examples of amino alcohols are 2-amino-1-ethanol, 3-amino-1-propanol, 4-amino-1-butanol, 5-amino-1-pentanol, 6-amino-1-hexanol, 3-amino-1, 2-propanediol, 2-amino-l, 3-propanediol, 3-amino-1, 2, 4-butanetriol, hydroxyaniline, 4-aminoresorcinol.
  • the signal molecule and the specifically binding structural unit are connected to one another via conventional functional groups.
  • groups are esters, ethers, secondary and tertiary amines, amides and the structures listed below
  • the compounds of the general formula I according to the invention are prepared by modifying polymethine dye base bodies which contain couplable functionalities (for example carboxyl, amino, hydroxyl groups) by the processes known to the person skilled in the art.
  • couplable functionalities for example carboxyl, amino, hydroxyl groups
  • the dye-biomolecule adducts according to the invention are prepared by reacting the dye with a biomolecule A using methods known from the literature.
  • the dyes must have reactive groups that can be coupled, or the dye must be activated by generating these groups in situ or beforehand.
  • Groups reactive towards amino and sulfhydryl groups of a biomolecule are, for example, N-hydroxysuccinimidyl esters, N-hydroxysuccinic acid imidyl ester 3 sulfate, isothiocyanates, isocyanates, maleimide, haloacetyl, vinyl sulfone groups.
  • the coupling is preferably carried out in an aqueous medium.
  • the degree of loading can be controlled by the stoichiometry and reaction time.
  • Literature Synth. Co mun. 23 (1993) 3078-94,
  • Another object of the present invention is the use of compounds of general formula I according to the invention for the in vivo diagnosis of neurodegenerative diseases by means of NIR radiation.
  • Another object of the present invention is the use of compounds of general formula I according to the invention for in vitro diagnostics.
  • tissue samples or biopsy samples are obtained and examined for their content of ⁇ -amyloid sheet structures.
  • the dyes of the invention bind selectively to the samples to be examined and allow an evaluation based on the specifically emitted fluorescence in the near-infrared spectral range.
  • the present invention further also relates to diagnostic agents for in vivo diagnostics, which contain compounds of the general formula I together with the customary auxiliaries and carriers and diluents.
  • one or more of the substances are added to the tissue when used for in vivo diagnostics, and light from the near-infrared spectral range is input. shine.
  • the non-absorbed, scattered light and / or the scattered fluorescent radiation emitted by the dye are registered simultaneously / individually.
  • Preferred are the methods in which the tissue is irradiated over a large area and the fluorescence radiation is displayed locally resolved by recording with a CCD camera or the tissue areas to be imaged are scanned with a light guide and the signals obtained are converted into a synthetic image by calculation.
  • the fluorescence can be evaluated spectrally and / or phase-selectively as well as stationary and / or time-resolved.
  • the particular advantage of the compounds according to the invention is that when stable dyes are used, the fluorescence signal can be generated and detected even after longer periods after application by excitation of the dye. There is a longer time window for diagnosis, as there are no limitations, for example due to decay half-lives.
  • the use according to the invention provides a non-invasive diagnostic method which enables the direct detection of the amyloid plaques in vivo.
  • the preparation is carried out analogously to Example 2, starting from 0.5 g (0.7 mmol) of 1,1 'bis (4-sulfo-butyl) indotricarbocyanine-5-carboxylic acid using 0.43 g (1.2 mmol) Chondrosin.
  • the reaction time is 5 hours.
  • the purification is carried out by means of HPLC (column: 250x20 mm, Nucleosil 100C18, 7 mm, eluent 50 mM phosphate buffer pH4 / MeOH, 5% to 95% MeOH in 60 min) with subsequent desalination on RP silica gel and freeze drying. Yield: 0.35 g (48%), blue lyophilisate
  • 0.2 g of maltotriose is stirred in 5 ml of a saturated ammonium bicarbonate at 30 ° C. for 7 days. To remove excess ammonium bicarbonate, the solution is repeatedly lyophilized to constant weight.
  • a solution of 0.1 g (0.14 mmol) of 1,1 'bis (4 -sulfobutyl) indotricarbocyanine-5-carboxylic acid and 15 mg of triethylamine in 5 ml of dimethylformamide is mixed with 0.05 g (0.15 mmol) O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyl-uronium tetrafluoroborate (TBTU) are added and the mixture is stirred at room temp. for 30 min. touched. Then 0.14 g (0.28 mmol) of 1-amino-1-deoxy-maltotriose are added and a further 5 h at room temperature. touched.
  • TBTU tetramethyl-uronium tetrafluoroborate
  • heparin low molecular weight, M approx. 6000 g / mol, Sigma
  • sulfated 25 ° C for 3 h; yield 0.20 g
  • 0.10 g of partially de-N-sulfated, low molecular weight heparin are dissolved in 40 ml of phosphate buffer (0.1 M ⁇ aH 2 P0 4 / Na 2 HP0 4 , pH 8.3) with a solution of 0.12 g (0.15 mmol) of 1,1'-bis (4-sulfo-butyl) indotricarbocyanine-5-carboxylic acid-N-hydroxysuccinimidyl ester, sodium salt (see Example 1) in 4 ml of dimethylformamide and 2 h at room temperature. touched. It is cleaned by means of ultrafiltration with dist. Water (Centriprep 3000, Amicon), freeze-drying and 5-hour. Drying at 50 ° C in a high vacuum.
  • phosphate buffer 0.1 M ⁇ aH 2 P0 4 / Na 2 HP0 4 , pH 8.3
  • the binding assay was carried out on ⁇ A4-peptide-coated nitrocellulose membranes (cellulose nitrate membrane filter CN; 0.4 ⁇ m, from Schleicher & Schuell).
  • the membrane was coated in a dot blot chamber (from Strategagen).
  • the membrane and the blotting paper (GB002, from Schleicher & Schuell) were moistened with water and in TBST buffer (20 mM Tris / HCl pH7, 6; 127 M NaCl; 0.1% Tween 20; 0.01% NaN 3 ) equilibrated.
  • the laser-induced fluorescence images are carried out on an experimental fluorescence imaging system.
  • the excitation took place with monochromatic laser light with a wavelength of 740 nm by coupling out the radiation via an optical fiber system and homogeneous illumination of the cellulose membranes.
  • the reflected excitation light is blocked by an edge filter, the laser-induced fluorescent light above 740 nm is recorded with a CCD camera (Charge Coupled Device) and the data is saved as black and white images.
  • 1 to 2 show examples of fluorescence images of the membranes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés de formule générale (I): Fm(-A1) (-Bn) (-Wo), dans laquelle F est une molécule signal de colorant présentant au moins une valeur d'absorption maximale comprise entre 600 et 1200 nm; A est une biomolécule se fixant sur les plaques de β-amyloïde; B est un colorant se fixant sur les plaques de β-amyloïde; W est un élément structural de faible poids moléculaire, hydrophile, se fixant sur les plaques de β-amyloïde. L'invention concerne également l'utilisation de ces composés pour le diagnostic in vivo et in vitro de maladies neurodégénératives, telles que la maladie d'Alzheimer, au moyen d'un rayonnement infrarouge proche servant d'agent de contraste dans le diagnostic par fluorescence et transillumination dans le domaine de l'infrarouge proche. L'invention concerne enfin des agents de diagnostic contenant lesdits composés.
EP97948710A 1996-11-19 1997-10-29 Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche Withdrawn EP0942756A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19649971 1996-11-19
DE19649971A DE19649971A1 (de) 1996-11-19 1996-11-19 Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung)
PCT/DE1997/002559 WO1998022146A2 (fr) 1996-11-19 1997-10-29 Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche

Publications (1)

Publication Number Publication Date
EP0942756A2 true EP0942756A2 (fr) 1999-09-22

Family

ID=7813413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97948710A Withdrawn EP0942756A2 (fr) 1996-11-19 1997-10-29 Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche

Country Status (8)

Country Link
US (1) US6329531B1 (fr)
EP (1) EP0942756A2 (fr)
JP (1) JP2001506591A (fr)
CN (1) CN1237911A (fr)
AU (1) AU7298598A (fr)
CA (1) CA2272320A1 (fr)
DE (1) DE19649971A1 (fr)
WO (1) WO1998022146A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
GB9812596D0 (en) * 1998-06-11 1998-08-12 Amersham Pharm Biotech Uk Ltd Energy transfer assay method
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US7547721B1 (en) 1998-09-18 2009-06-16 Bayer Schering Pharma Ag Near infrared fluorescent contrast agent and fluorescence imaging
US20030180221A1 (en) * 1998-09-18 2003-09-25 Schering Ag Near infrared fluorescent contrast agent and fluorescence imaging
US7175953B2 (en) 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
US6630570B1 (en) 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
US6217848B1 (en) * 1999-05-20 2001-04-17 Mallinckrodt Inc. Cyanine and indocyanine dye bioconjugates for biomedical applications
USRE39105E1 (en) 1999-06-21 2006-05-23 Yamamoto Chemicals, Inc. Polymethine compounds, method of producing same, and use thereof
US6939532B2 (en) * 2000-01-18 2005-09-06 Mallinckrodt, Inc. Versatile hydrophilic dyes
US6180085B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Dyes
US7198778B2 (en) 2000-01-18 2007-04-03 Mallinckrodt Inc. Tumor-targeted optical contrast agents
US7790144B2 (en) 2000-01-18 2010-09-07 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
US6180087B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US6395257B1 (en) 2000-01-18 2002-05-28 Mallinckrodt Inc. Dendrimer precursor dyes for imaging
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
DE10023051B4 (de) * 2000-05-11 2004-02-19 Roche Diagnostics Gmbh Verfahren zur Herstellung von Fluoresceinisothiocyanat-Sinistrin, dessen Verwendung und Fluoresceinisothiocyanat-Sinistrin enthaltende diagnostische Zubereitung
US7297326B2 (en) 2000-08-21 2007-11-20 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
EP1322959A1 (fr) * 2000-08-21 2003-07-02 The General Hospital Corporation Methodes permettant de diagnostiquer un etat neurodegeneratif
DE10046215B4 (de) * 2000-09-19 2004-04-15 Institut für Chemo- und Biosensorik Münster e.V. i.Ins. Fluorochrome und deren Verwendung
US7597878B2 (en) * 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
US6673334B1 (en) * 2000-10-16 2004-01-06 Mallinkcrodt, Inc. Light sensitive compounds for instant determination of organ function
WO2002038190A2 (fr) 2000-10-27 2002-05-16 Beth Israel Deaconess Medical Center Detection non isotopique d'une activite osteoblastique in vivo a l'aide de bisphosphonates modifies
DE60128138T2 (de) * 2000-11-02 2008-01-03 Cornell Research Foundation, Inc. In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung
JP2005511498A (ja) * 2001-04-27 2005-04-28 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド アルツハイマー病の視覚診断
US6761878B2 (en) * 2001-10-17 2004-07-13 Mallinckrodt, Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
US20030105300A1 (en) 2001-10-17 2003-06-05 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
WO2003079015A1 (fr) * 2002-03-11 2003-09-25 Visen Medical, Inc. Sondes pour imagerie optique
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
CA2514200A1 (fr) * 2003-01-22 2004-08-05 The General Hospital Corporation Agent de chelation metallique, a liaison amyloide
WO2004080285A2 (fr) * 2003-03-10 2004-09-23 Michigan State University Plaque amyloide utilisee comme cible pour des therapies qui fonctionnent en bloquant ou en interrompant la synthese ou l'activite de la chitine
WO2005000218A2 (fr) 2003-05-31 2005-01-06 Washington University Bioconjugues macrocycliques a base de cyanine et d'indocyanine pour applications biomedicales ameliorees
CA2535873A1 (fr) * 2003-08-18 2005-02-24 Novartis Ag Derives de 3h-phenoxazine utilises en tant qu'agents d'imagerie infrarouge, leur preparation et leur utilisation
DE102004002758A1 (de) * 2004-01-20 2005-08-04 Bayer Chemicals Ag Metallkomplexe als lichtabsorbierende Verbindungen in der Informationsschicht von optischen Datenträgern
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
DE102004061064A1 (de) * 2004-12-18 2006-06-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur spektroskopischen Untersuchung von Körperflüssigkeiten und Gewebeproben hinsichtlich eines erhöhten Alzheimerverdachts
EP1901781A2 (fr) * 2005-06-21 2008-03-26 Mallinckrodt, Inc. Agents de contraste d'imagerie optique
EP2382915B1 (fr) * 2006-04-11 2020-06-24 Cognoptix, Inc. Imagerie oculaire
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US20090214436A1 (en) 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
MX2010010402A (es) * 2008-03-27 2010-12-17 Neuroptix Corp Formacion de imagenes oculares.
US7956169B1 (en) * 2010-06-16 2011-06-07 Chemgenes Corporation Synthesis of novel azo-dyes and their use in oligonucleotide synthesis
JP5863797B2 (ja) 2010-08-16 2016-02-17 コグノプティックス， インコーポレイテッド アミロイドタンパク質を検出するためのデバイス
EP2806781B1 (fr) 2012-01-23 2018-03-21 Washington University Systèmes et procédés d'imagerie
EP2878335B1 (fr) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant et système d'implantation pour stimulateur neural
WO2016179350A1 (fr) 2015-05-06 2016-11-10 Washington University Composés à motifs de ciblage rd et leurs procédés d'utilisation
EP3093043B1 (fr) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant et système de distribution pour stimulateur neural
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US10842887B2 (en) 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
JP2022532628A (ja) 2019-05-13 2022-07-15 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 修飾シアニン色素およびそのコンジュゲート
WO2021119423A1 (fr) 2019-12-13 2021-06-17 Washington University Colorants fluorescents dans l'infrarouge proche, formulations et procédés associés
AU2021295552A1 (en) * 2020-06-23 2022-11-03 Bracco Imaging Spa Near-infrared cyanine dyes and conjugates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2676117B2 (ja) * 1990-11-22 1997-11-12 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9822146A2 *

Also Published As

Publication number Publication date
CN1237911A (zh) 1999-12-08
US6329531B1 (en) 2001-12-11
JP2001506591A (ja) 2001-05-22
WO1998022146A3 (fr) 1998-10-15
WO1998022146A2 (fr) 1998-05-28
CA2272320A1 (fr) 1998-05-28
AU7298598A (en) 1998-06-10
DE19649971A1 (de) 1998-05-28

Similar Documents

Publication Publication Date Title
WO1998022146A2 (fr) Agents pour etablir un diagnostic par voie optique de maladies neurodegeneratives au moyen d'un rayonnement infrarouge proche
EP0988060B1 (fr) Colorants de synthese labiles aux acides et clivables par voie enzymatique pour le diagnostic avec de la lumiere dans le proche infrarouge et pour l'usage therapeutique
EP1181940B1 (fr) Procédé de diagnostique in vivo par rayons infrarouges proches
DE69911034T2 (de) Im nahinfrarotbereich fluoreszierende kontrastmittel und fluoreszenzbildgebung
DE69923859T2 (de) Porphyrin-Verbindungen, ihre Konjugate und Testmethoden basierend auf der Verwendung besagter Konjugate
US5672333A (en) Delta1,6 bicyclo 4,4,0! functional dyes for contrast enhancement in optical imaging
DE202014008232U1 (de) Eine doppelt markierte Sonde für die molekulare Bildgebung und deren Verwendung
EP1088558B1 (fr) Formulations galéniques comprenant des composés paramagnétiques et diamagnétiques
CH640826A5 (de) L-gamma-glutamyl-3-carboxy-4-hydroxyanilid und dessen salze, verfahren zu dessen herstellung und dessen verwendung zur bestimmung der aktivitaet von gamma-glutamyltranspeptidase.
JP2003527447A (ja) 新規染料−ポリサッカライドコンジュゲート及びそれらの診断剤としての使用
EP1809340B1 (fr) Substances marquees avec des colorants de facon stoechiometrique pour mesurer le taux de la filtration renale
DE69921151T2 (de) Fluorszierende marker
EP1307446B1 (fr) Complexes perfluoroalkyles a residus saccharides, leur procede de fabrication et leur utilisation
RU2290206C2 (ru) Применение перфторалкилсодержащих комплексов металлов в качестве контрастных веществ в магнитно-резонансной томографии для визуализации бляшек, опухолей и некрозов
EP1088559A2 (fr) Formulations galéniques
WO2001023005A1 (fr) Conjugues anticorps-colorant contre des structures cibles de l'angiogenese pour une representation peroperatoire de bord de tumeur
DE60016323T2 (de) Neue Pyrylium Verbindung, Verfahren zu ihrer Herstellung, Nucleinsäure-Färbemittel und markierte Nucleinsäure
CN111072584B (zh) 一种近红外荧光小分子探针及其制备与应用
DE602004004280T2 (de) Als mittel zur nahinfrarotabbildung geeignete 3h-phenoxazinderivate, deren herstellung und verwendung
EP1170021A2 (fr) Conjugués de peptides et de complexes de lanthanides comme agent de contraste fluorescent pour diagnostique
DE60033640T2 (de) Kolorimetrisches bestimmungsverfahren
DE10302787A1 (de) Hydrophile, Thiol-reaktive Cyaninfarbstoffe und deren Konjugate mit Biomolekülen für die Fluoreszenzdiagnostik
DE3634496A1 (de) Glukosylmoranolinderivate und ihre herstellung
DE10040380B4 (de) Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
CN116393690A (zh) Zw800-1修饰的银纳米颗粒及应用于制备诊断肾损伤的产品以及制法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990429

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUT FUER DIAGNOSTIKFORSCHUNG GMBH AN DER FREI

17Q First examination report despatched

Effective date: 20070810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091104